Cargando…

Oleanolic Acid (OA) Targeting UNC5B Inhibits Proliferation and EMT of Ovarian Cancer Cell and Increases Chemotherapy Sensitivity of Niraparib

OBJECTIVE: To investigate the effect of OA on proliferation, migration, and epithelial-mesenchymal transition (EMT) of ovarian cancer cells by inhibiting UNC5B and to study its mechanism. METHODS: TCGA database was used to analyze the expression of UNC5B in ovarian cancer and its relationship with p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zeng, Zhen, Yu, Jing, Jiang, Zhongqing, Zhao, Ningwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8758276/ https://www.ncbi.nlm.nih.gov/pubmed/35035481 http://dx.doi.org/10.1155/2022/5887671

Ejemplares similares

Curcumol Targeting PAX8 Inhibits Ovarian Cancer Cell Migration and Invasion and Increases Chemotherapy Sensitivity of Niraparib
por: Liu, Caihong
Publicado: (2022)

Niraparib for ovarian cancer
Publicado: (2021)

Rucaparib and Niraparib in Advanced Ovarian Cancer
por: Redelico, Tyler
Publicado: (2019)

Niraparib in ovarian cancer: results to date and clinical potential
por: Caruso, Davide, et al.
Publicado: (2017)

Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive Recurrent Ovarian Cancer
por: Zhong, Lixian, et al.
Publicado: (2018)

Safety and management of niraparib monotherapy in ovarian cancer clinical trials
por: Monk, Bradley J, et al.
Publicado: (2023)

Niraparib-induced STAT3 inhibition increases its antitumor effects
por: Zhao, Qianqian, et al.
Publicado: (2022)

How to start niraparib in real-world Asian ovarian cancer patients?
por: Hong, Sook-Hee
Publicado: (2021)

Case Report: Niraparib as Maintenance Therapy in A Patient With Ovarian Carcinosarcoma
por: Zhang, Jie Qing, et al.
Publicado: (2021)

Pharmacological effects of Niraparib and its combination with angiogenic inhibitor in ovarian cancer
por: Liu, Huiwen, et al.
Publicado: (2023)

Cost-effectiveness of maintenance niraparib with an individualized starting dosage in patients with platinum-sensitive recurrent ovarian cancer in China
por: Shi, Yin, et al.
Publicado: (2023)

PARP Inhibitors Talazoparib and Niraparib Sensitize Melanoma Cells to Ionizing Radiation
por: Jonuscheit, Stephanie, et al.
Publicado: (2021)

Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer
por: Lee, Arnold
Publicado: (2021)

Niraparib and Advanced Ovarian Cancer: A Beacon in the Non-BRCA Mutated Setting
por: Maiorano, Mauro Francesco Pio, et al.
Publicado: (2023)

Phase 2 single-arm study on the safety of maintenance niraparib in Japanese patients with platinum-sensitive relapsed ovarian cancer
por: Takehara, Kazuhiro, et al.
Publicado: (2021)

An In-Depth Review of Niraparib in Ovarian Cancer: Mechanism of Action, Clinical Efficacy and Future Directions
por: Akay, Melek, et al.
Publicado: (2021)

Correction to: Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer
por: Lee, Arnold
Publicado: (2021)

Inhibiting PRMT5 induces DNA damage and increases anti-proliferative activity of Niraparib, a PARP inhibitor, in models of breast and ovarian cancer
por: O’Brien, Shane, et al.
Publicado: (2023)

The UNC-6/Netrin receptors UNC-40/DCC and UNC-5 inhibit growth cone filopodial protrusion via UNC-73/Trio, Rac-like GTPases and UNC-33/CRMP
por: Norris, Adam D., et al.
Publicado: (2014)

Expression of PnSS Promotes Squalene and Oleanolic Acid (OA) Accumulation in Aralia elata via Methyl Jasmonate (MeJA) Induction
por: Xu, Honghao, et al.
Publicado: (2023)

unc-119 mutants have an increased fungal spore adhesion that is not rescued by Cb-unc-119
por: Omi, Shizue, et al.
Publicado: (2021)

The efficacy and safety of niraparib for ovarian cancer: a single-center observational study from China
por: Ni, Jing, et al.
Publicado: (2021)

Safety Profile of Niraparib as Maintenance Therapy for Ovarian Cancer: A Systematic Review and Meta-Analysis
por: Pagkali, Antonia, et al.
Publicado: (2022)

Cisplatin and oleanolic acid Co-loaded pH-sensitive CaCO(3) nanoparticles for synergistic chemotherapy
por: Khan, Muhammad Waseem, et al.
Publicado: (2022)

First-line maintenance therapy with niraparib in advanced platinum-sensitive ovarian cancer: two ‘long responder’ case reports and review of the current literature
por: Ngan, Roger K. C.
Publicado: (2023)

UNC13C Suppress Tumor Progression via Inhibiting EMT Pathway and Improves Survival in Oral Squamous Cell Carcinoma
por: Velmurugan, Bharath Kumar, et al.
Publicado: (2019)

Case Report: Niraparib-Related Pulmonary Embolism During the Treatment of BRCA Mutant Advanced Ovarian Cancer
por: Wei, Qiang, et al.
Publicado: (2022)

A phase 1 evaluation of the safety and tolerability of niraparib in combination with everolimus in advanced ovarian and breast cancers
por: Starks, David, et al.
Publicado: (2023)

UNC-129 regulates the balance between UNC-40 dependent and independent UNC-5 signaling pathways
por: MacNeil, Lesley T., et al.
Publicado: (2009)

Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial
por: del Campo, Josep M., et al.
Publicado: (2019)

A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study
por: Shi, Tingyan, et al.
Publicado: (2020)

Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment
por: Akce, Mehmet, et al.
Publicado: (2021)

YAP and 14-3-3γ are involved in HS-OA-induced growth inhibition of hepatocellular carcinoma cells: A novel mechanism for hydrogen sulfide releasing oleanolic acid
por: Xu, Guanglin, et al.
Publicado: (2016)

Haploinsufficiency of UNC13D increases the risk of lymphoma
por: Löfstedt, Alexandra, et al.
Publicado: (2019)

Niraparib exhibits a synergistic anti-tumor effect with PD-L1 blockade by inducing an immune response in ovarian cancer
por: Meng, Jinyu, et al.
Publicado: (2021)

FRI617 Targeting Unc119b For Insulin Sensitization
por: Mittal, Ayushi, et al.
Publicado: (2023)

Real‐world outcomes of niraparib treatment in patients with ovarian cancer: a multicenter non‐interventional study in China
por: Li, Jin, et al.
Publicado: (2023)

Addendum: A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study
por: Shi, Tingyan, et al.
Publicado: (2022)

Targeting MUCL1 protein inhibits cell proliferation and EMT by deregulating β-catenin and increases irinotecan sensitivity in colorectal cancer
por: Abdulla, Maha, et al.
Publicado: (2022)

Oleanolic acid ethanol monosolvate
por: Froelich, Anna, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_vfu90l93ptopabvmpo23rcai44